FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2346243878> ?p ?o ?g. }

• W2346243878 endingPage "8270" @default.
• W2346243878 startingPage "8265" @default.
• W2346243878 abstract "A cost-utility analysis was performed to assess the cost-utility of neoadjuvant chemotherapy regimens containing doxorubicin and cyclophosphamide (AC) versus paclitaxel and gemcitabine (PG) for locally advanced breast cancer patients in Iran.This cross-sectional study in Namazi hospital in Shiraz, in the south of Iran covered 64 breast cancer patients. According to the random numbers, the patients were divided into two groups, 32 receiving AC and 32 PG. Costs were identified and measured from a community perspective. These items included medical and non-medical direct and indirect costs. In this study, a data collection form was used. To assess the utility of the two regimens, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) was applied. Using a decision tree, we calculated the expected costs and quality adjusted life years (QALYs) for both methods; also, the incremental cost-effectiveness ratio was assessed.The results of the decision tree showed that in the AC arm, the expected cost was 39,170 US$ and the expected QALY was 3.39 and in the PG arm, the expected cost was 43,336 dollars and the expected QALY was 2.64. Sensitivity analysis showed the cost effectiveness of the AC and ICER=-5535 US$.Overall, the results showed that AC to be superior to PG in treatment of patients with breast cancer, being less costly and more effective." @default.
• W2346243878 created "2016-06-24" @default.
• W2346243878 creator A5000307269 @default.
• W2346243878 creator A5012905601 @default.
• W2346243878 creator A5033597376 @default.
• W2346243878 creator A5034365402 @default.
• W2346243878 creator A5054846393 @default.
• W2346243878 date "2016-01-11" @default.
• W2346243878 modified "2023-10-13" @default.
• W2346243878 title "Cost-Utility of Doxorubicin and Cyclophosphamide versus Gemcitabine and Paclitaxel for Treatment of Patients with Breast Cancer in Iran" @default.
• W2346243878 cites W1573092078 @default.
• W2346243878 cites W1972140297 @default.
• W2346243878 cites W1975939084 @default.
• W2346243878 cites W1994858703 @default.
• W2346243878 cites W2006425178 @default.
• W2346243878 cites W2035009439 @default.
• W2346243878 cites W2039455259 @default.
• W2346243878 cites W2053517014 @default.
• W2346243878 cites W2055175022 @default.
• W2346243878 cites W2074668580 @default.
• W2346243878 cites W2076134069 @default.
• W2346243878 cites W2082347947 @default.
• W2346243878 cites W2090311448 @default.
• W2346243878 cites W2106787323 @default.
• W2346243878 cites W2143458089 @default.
• W2346243878 cites W2159102253 @default.
• W2346243878 cites W2164194457 @default.
• W2346243878 cites W2169906750 @default.
• W2346243878 cites W2172229147 @default.
• W2346243878 cites W2328777485 @default.
• W2346243878 doi "https://doi.org/10.7314/apjcp.2015.16.18.8265" @default.
• W2346243878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26745071" @default.
• W2346243878 hasPublicationYear "2016" @default.
• W2346243878 type Work @default.
• W2346243878 sameAs 2346243878 @default.
• W2346243878 citedByCount "8" @default.
• W2346243878 countsByYear W23462438782017 @default.
• W2346243878 countsByYear W23462438782018 @default.
• W2346243878 countsByYear W23462438782021 @default.
• W2346243878 countsByYear W23462438782022 @default.
• W2346243878 countsByYear W23462438782023 @default.
• W2346243878 crossrefType "journal-article" @default.
• W2346243878 hasAuthorship W2346243878A5000307269 @default.
• W2346243878 hasAuthorship W2346243878A5012905601 @default.
• W2346243878 hasAuthorship W2346243878A5033597376 @default.
• W2346243878 hasAuthorship W2346243878A5034365402 @default.
• W2346243878 hasAuthorship W2346243878A5054846393 @default.
• W2346243878 hasBestOaLocation W23462438781 @default.
• W2346243878 hasConcept C112930515 @default.
• W2346243878 hasConcept C121608353 @default.
• W2346243878 hasConcept C126322002 @default.
• W2346243878 hasConcept C127454912 @default.
• W2346243878 hasConcept C143998085 @default.
• W2346243878 hasConcept C159110408 @default.
• W2346243878 hasConcept C184834754 @default.
• W2346243878 hasConcept C18903297 @default.
• W2346243878 hasConcept C2776694085 @default.
• W2346243878 hasConcept C2776755627 @default.
• W2346243878 hasConcept C2779951463 @default.
• W2346243878 hasConcept C2780258809 @default.
• W2346243878 hasConcept C29456083 @default.
• W2346243878 hasConcept C3019080777 @default.
• W2346243878 hasConcept C530470458 @default.
• W2346243878 hasConcept C64332521 @default.
• W2346243878 hasConcept C71924100 @default.
• W2346243878 hasConcept C86803240 @default.
• W2346243878 hasConceptScore W2346243878C112930515 @default.
• W2346243878 hasConceptScore W2346243878C121608353 @default.
• W2346243878 hasConceptScore W2346243878C126322002 @default.
• W2346243878 hasConceptScore W2346243878C127454912 @default.
• W2346243878 hasConceptScore W2346243878C143998085 @default.
• W2346243878 hasConceptScore W2346243878C159110408 @default.
• W2346243878 hasConceptScore W2346243878C184834754 @default.
• W2346243878 hasConceptScore W2346243878C18903297 @default.
• W2346243878 hasConceptScore W2346243878C2776694085 @default.
• W2346243878 hasConceptScore W2346243878C2776755627 @default.
• W2346243878 hasConceptScore W2346243878C2779951463 @default.
• W2346243878 hasConceptScore W2346243878C2780258809 @default.
• W2346243878 hasConceptScore W2346243878C29456083 @default.
• W2346243878 hasConceptScore W2346243878C3019080777 @default.
• W2346243878 hasConceptScore W2346243878C530470458 @default.
• W2346243878 hasConceptScore W2346243878C64332521 @default.
• W2346243878 hasConceptScore W2346243878C71924100 @default.
• W2346243878 hasConceptScore W2346243878C86803240 @default.
• W2346243878 hasIssue "18" @default.
• W2346243878 hasLocation W23462438781 @default.
• W2346243878 hasLocation W23462438782 @default.
• W2346243878 hasOpenAccess W2346243878 @default.
• W2346243878 hasPrimaryLocation W23462438781 @default.
• W2346243878 hasRelatedWork W2013924785 @default.
• W2346243878 hasRelatedWork W2029073387 @default.
• W2346243878 hasRelatedWork W2034847231 @default.
• W2346243878 hasRelatedWork W2041145027 @default.
• W2346243878 hasRelatedWork W2105414750 @default.
• W2346243878 hasRelatedWork W2153547577 @default.
• W2346243878 hasRelatedWork W2159627298 @default.
• W2346243878 hasRelatedWork W2346243878 @default.
• W2346243878 hasRelatedWork W4214934539 @default.

• next